Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STM-416
- Development stage
- Phase 2
- Lead developer
- SURGE Therapeutics
- Modality
- Hydrogel Systems → Drug Delivery Systems, Small Molecules
- Administration
- Intravesical, Intralesional
01
Overview
**STM-416** is SURGE Therapeutics' investigational intraoperative immunotherapy for recurrent high-grade non-muscle-invasive bladder cancer. It is an injectable, biodegradable, extended-release hydrogel formulation containing **resiquimod**, a small-molecule Toll-like receptor 7 and Toll-like receptor 8 agonist. STM-416 is injected locally into the tumor-resection site during transurethral resection of bladder tumor to sustain local resiquimod exposure, stimulate innate immune cells, and promote antitumor immune responses intended to eliminate residual tumor cells and reduce post-surgical recurrence or progression. STM-416 is being evaluated in the first-in-human Phase 1/2a study NCT05710848.
- Other names
- hydrogel-based resiquimod STM-416resiquimod-containing hydrogel STM-416
02
Targets
TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on STM-416.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STM-416.